HCC

Initial Therapy Options for Liver Cancer

Liver-Directed and Systemic Therapy in HCC

HCC: Multidisciplinary Assessment and Liver Transplant

Prognosis of Metastatic Liver Cancer

Latest Videos

An Overview of the TRK Inhibition Landscape

Identifying TRK-Driven Disease Amid Tumor Types

Evolution in Cancer Treatment: Tropomyosin Receptor Kinases

TRK Inhibitors: A Tumor Agnostic Targeted Therapy

Data Suggest Potential for Immunotherapy in HCC

Appropriate Management of Patients With Metastatic HCC

Treatment Approach to Metastatic Hepatocellular Carcinoma

Diagnostic Workup & Initial Treatment for HCC

Case Review: Metastatic HCC and a History of HCV

Unresectable HCC with a History of Hepatitis C Virus

CME Content

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Manmeet Ahluwalia, MD, MBA

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD; Benjamin Falit, MD; Jami Fukui, MD; Laura Huppert, MD; Sara A. Hurvitz, MD, FACP; Jodi Kagihara, MD; Irene Kang, MD; William Loui, MD, FACP; Ashley Marumoto, MD; Rebecca Shatsky, MD; Naoko Takebe, MD, PhD; Melinda Telli, MD, FASCO; Rachel Thelen, FNP-C, AOCNP; Teruo Yamauchi, MD, MS

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Managing Metastatic Hepatocellular Carcinoma

April 25th 2018

Managing Metastatic Hepatocellular Carcinoma

Becerra Shares Treatment Considerations in 2 Gastrointestinal Case Studies

ByGhassan K. Abou-Alfa, MD

April 10th 2018

Carlos Becerra, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer and hepatocellular carcinoma. Becerra, a medical oncologist at Texas Oncology, Baylor Charles A. Sammons Cancer Center, explained his treatment decisions based on 2 case scenarios during a Targeted Oncology live case-based peer perspectives presentation.

Results From the CELESTIAL Trial for Patients with Advanced HCC

April 10th 2018

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes. 

Top-Line Results Show Ramucirumab Improves Survival in Second-Line HCC

ByJason Harris

April 10th 2018

Overall survival was extended in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (AFP) who received second-line treatment with ramucirumab (Cyramza) versus placebo, according to findings from the phase III REACH-2 trial.

T-VEC Injections Safe in Patients with Advanced-Stage Liver Metastases

March 29th 2018

According to early results of an ongoing early-phase study presented at the 2018 Society of Interventional Radiology Annual Scientific Meeting, image-guided injections of talimogene laherparepvec immunotherapy (T-VEC, Imylgic) were deemed tolerable in patients with advanced-stage liver metastases.

Evolving Treatment Landscape in Locally Advanced NSCLC

March 20th 2018

Practical Considerations for Durvalumab in Stage 3 NSCLC

March 20th 2018

Locally Advanced NSCLC: Durvalumab and the PACIFIC Trial

March 20th 2018

Unmet Needs and Role of Immunotherapy in Stage 3 NSCLC

March 20th 2018

Chemotherapy Approaches in Locally Advanced NSCLC

March 20th 2018

Locally Advanced NSCLC: Workup and Treatment Approach

March 20th 2018

Immunotherapy in Unresectable Locally Advanced NSCLC

March 20th 2018

Lung Cancer

SIRT Better Tolerated Than Sorafenib in Patients With Unresectable HCC

March 19th 2018

Selective internal radiation therapy with yttrium-90 resin microspheres was better tolerated compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma, However, findings from the phase III SARAH trial did not improve rates of overall survival or progression-free survival. A radiotherapy approach was compared with this targeted therapy in the SARAH trial.

Eisai And Merck Collaboration Initiated for the Advancement of Lenvatinib Mesylate